Northwestern INVO Innovation Fund + Translational Med
Provides Northwestern spinouts with translational support and early commercialization funding for technical ventures.
Northwestern INVO Innovation Fund + Translational Med sits inside Northwestern INVO and the Feinberg School of Medicine. It is a university translational grant program for Northwestern faculty-led spinouts and research teams, with a focus on life sciences, medtech, and manufacturing. The notes connect it to the N.XT Fund and Feinberg Translational Medicine Innovation Awards. The award range runs from about $50,000 to $250,000, with a median actual award of $150,000 and an annual cycle. For-profit companies are allowed, nonprofits and individuals are not, and the eligibility window runs from TRL 2 to TRL 5. The program is positioned for Northwestern-affiliated teams rather than external applicants. The best fit is translational work that needs a proof-of-concept infusion before a larger raise or licensing step. Because the program is narrow on eligibility and stage, teams improve their odds by showing a clear technical rationale, a plausible path to application, and a credible plan for the next development milestone. It is a conventional university commercialization grant, not a general-purpose award.
No upcoming rounds verified. Cadence: Annual.